Press release
Cognitive Impairment Associated with Schizophrenia Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Cyclerion Therapeutics, Biogen, Neurocrine Bioscien
"Cognitive Impairment Associated with Schizophrenia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cognitive Impairment Associated with Schizophrenia Market.
The Cognitive Impairment Associated with Schizophrenia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Cognitive Impairment Associated with Schizophrenia Pipeline Report: https://www.delveinsight.com/sample-request/cognitive-impairment-associated-with-schizophrenia-cias-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Cognitive Impairment Associated with Schizophrenia treatment therapies with a considerable amount of success over the years.
• Cognitive Impairment Associated with Schizophrenia companies working in the treatment market are Autifony Therapeutics, Cyclerion Therapeutics, Biogen, Neurocrine Biosciences, Recognify Life Sciences, Boehringer Ingelheim, Memory Pharmaceuticals, Amarantus BioScience, Neurocrine Biosciences, Hoffmann-La Roche, Eli Lilly and Company, Cephalon, Johnson & Johnson Pharma, and others, are developing therapies for the Cognitive Impairment Associated with Schizophrenia treatment
• Emerging Cognitive Impairment Associated with Schizophrenia therapies in the different phases of clinical trials are- Research programme, CY6463, BIIB104, Luvadaxistat, RL-007, Iclepertin, MEM 3454, Eltoprazine, Luvadaxistat, Basmisanil, LY500307, armodafinil, Extended-release galantamine hydrobromide, and others are expected to have a significant impact on the Cognitive Impairment Associated with Schizophrenia market in the coming years.
• In April 2024, Alto Neuroscience has announced positive outcomes from its Phase I clinical trial of the PDE4 inhibitor ALTO-101 for treating cognitive impairment associated with schizophrenia (CIAS). The study showed that ALTO-101, delivered via a transdermal delivery system (TDS), had better tolerability and improved pharmacokinetics compared to oral administration. The Phase I trial aimed to evaluate the safety, tolerability, pharmacokinetics, and adhesion properties of the transdermal formulation of ALTO-101, in contrast to its oral form, in healthy volunteers.
• In March 2022, In order to assess the long-term safety of BI 425809 once daily in patients with schizophrenia who have successfully completed prior BI 425809 Phase III trials (CONNEX-X), Boehringer Ingelheim started an open-label, single-arm extension experiment.
Cognitive Impairment Associated with Schizophrenia Overview
Cognitive impairment associated with schizophrenia (CIAS) refers to the deficits in various cognitive functions experienced by individuals with schizophrenia. These cognitive deficits are a core feature of the disorder and can significantly impact daily functioning, social interactions, and overall quality of life.
Get a Free Sample PDF Report to know more about Cognitive Impairment Associated with Schizophrenia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cognitive-impairment-associated-with-schizophrenia-cias-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Cognitive Impairment Associated with Schizophrenia Drugs Under Different Phases of Clinical Development Include:
• Research programme: Autifony Therapeutics
• CY6463: Cyclerion Therapeutics
• BIIB104: Biogen
• Luvadaxistat: Neurocrine Biosciences
• RL-007: Recognify Life Sciences
• Iclepertin: Boehringer Ingelheim
• MEM 3454: Memory Pharmaceuticals
• Eltoprazine: Amarantus BioScience
• Luvadaxistat: Neurocrine Biosciences
• Basmisanil: Hoffmann-La Roche
• LY500307: Eli Lilly and Company
• armodafinil: Cephalon
• Extended-release galantamine hydrobromide: Johnson & Johnson Pharma
• Luvadaxistat: Takeda
Cognitive Impairment Associated with Schizophrenia Route of Administration
Cognitive Impairment Associated with Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Cognitive Impairment Associated with Schizophrenia Molecule Type
Cognitive Impairment Associated with Schizophrenia Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
Cognitive Impairment Associated with Schizophrenia Pipeline Therapeutics Assessment
• Cognitive Impairment Associated with Schizophrenia Assessment by Product Type
• Cognitive Impairment Associated with Schizophrenia By Stage and Product Type
• Cognitive Impairment Associated with Schizophrenia Assessment by Route of Administration
• Cognitive Impairment Associated with Schizophrenia By Stage and Route of Administration
• Cognitive Impairment Associated with Schizophrenia Assessment by Molecule Type
• Cognitive Impairment Associated with Schizophrenia by Stage and Molecule Type
DelveInsight's Cognitive Impairment Associated with Schizophrenia Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Cognitive Impairment Associated with Schizophrenia product details are provided in the report. Download the Cognitive Impairment Associated with Schizophrenia pipeline report to learn more about the emerging Cognitive Impairment Associated with Schizophrenia therapies at:
https://www.delveinsight.com/sample-request/cognitive-impairment-associated-with-schizophrenia-cias-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Cognitive Impairment Associated with Schizophrenia Therapeutics Market include:
Key companies developing therapies for Cognitive Impairment Associated with Schizophrenia are - Autifony Therapeutics Ltd, Boehringer Ingelheim International GmbH, Neurocrine Biosciences Inc, Novartis AG, Suven Life Sciences Ltd, Accure Therapeutics SL, Anvyl LLC, Astellas Pharma Inc, AstraZeneca Plc, Atai Life Sciences NV, and others.
Cognitive Impairment Associated with Schizophrenia Pipeline Analysis:
The Cognitive Impairment Associated with Schizophrenia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Cognitive Impairment Associated with Schizophrenia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cognitive Impairment Associated with Schizophrenia Treatment.
• Cognitive Impairment Associated with Schizophrenia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cognitive Impairment Associated with Schizophrenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cognitive Impairment Associated with Schizophrenia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Cognitive Impairment Associated with Schizophrenia drugs and therapies-
https://www.delveinsight.com/sample-request/cognitive-impairment-associated-with-schizophrenia-cias-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Cognitive Impairment Associated with Schizophrenia Pipeline Market Drivers
• Increase in Prevalence of Mental Disturbances, rise in Awareness About Mental Health are some of the important factors that are fueling the Cognitive Impairment Associated with Schizophrenia Market.
Cognitive Impairment Associated with Schizophrenia Pipeline Market Barriers
• However, side-effects associated with the treatment of Cognitive Impairment Associated with Schizophrenia, stigma associated with mental illness and other factors are creating obstacles in the Cognitive Impairment Associated with Schizophrenia Market growth.
Scope of Cognitive Impairment Associated with Schizophrenia Pipeline Drug Insight
• Coverage: Global
• Key Cognitive Impairment Associated with Schizophrenia Companies: Autifony Therapeutics, Cyclerion Therapeutics, Biogen, Neurocrine Biosciences, Recognify Life Sciences, Boehringer Ingelheim, Memory Pharmaceuticals, Amarantus BioScience, Neurocrine Biosciences, Hoffmann-La Roche, Eli Lilly and Company, Cephalon, Johnson & Johnson Pharma, and others
• Key Cognitive Impairment Associated with Schizophrenia Therapies: Research programme, CY6463, BIIB104, Luvadaxistat, RL-007, Iclepertin, MEM 3454, Eltoprazine, Luvadaxistat, Basmisanil, LY500307, armodafinil, Extended-release galantamine hydrobromide, and others
• Cognitive Impairment Associated with Schizophrenia Therapeutic Assessment: Cognitive Impairment Associated with Schizophrenia current marketed and Cognitive Impairment Associated with Schizophrenia emerging therapies
• Cognitive Impairment Associated with Schizophrenia Market Dynamics: Cognitive Impairment Associated with Schizophrenia market drivers and Cognitive Impairment Associated with Schizophrenia market barriers
Request for Sample PDF Report for Cognitive Impairment Associated with Schizophrenia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/cognitive-impairment-associated-with-schizophrenia-cias-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Cognitive Impairment Associated with Schizophrenia Report Introduction
2. Cognitive Impairment Associated with Schizophrenia Executive Summary
3. Cognitive Impairment Associated with Schizophrenia Overview
4. Cognitive Impairment Associated with Schizophrenia- Analytical Perspective In-depth Commercial Assessment
5. Cognitive Impairment Associated with Schizophrenia Pipeline Therapeutics
6. Cognitive Impairment Associated with Schizophrenia Late Stage Products (Phase II/III)
7. Cognitive Impairment Associated with Schizophrenia Mid Stage Products (Phase II)
8. Cognitive Impairment Associated with Schizophrenia Early Stage Products (Phase I)
9. Cognitive Impairment Associated with Schizophrenia Preclinical Stage Products
10. Cognitive Impairment Associated with Schizophrenia Therapeutics Assessment
11. Cognitive Impairment Associated with Schizophrenia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Cognitive Impairment Associated with Schizophrenia Key Companies
14. Cognitive Impairment Associated with Schizophrenia Key Products
15. Cognitive Impairment Associated with Schizophrenia Unmet Needs
16 . Cognitive Impairment Associated with Schizophrenia Market Drivers and Barriers
17. Cognitive Impairment Associated with Schizophrenia Future Perspectives and Conclusion
18. Cognitive Impairment Associated with Schizophrenia Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Cognitive Impairment Associated with Schizophrenia Market https://www.delveinsight.com/report-store/cognitive-impairment-associated-with-schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Cognitive Impairment Associated with Schizophrenia Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Cognitive Impairment Associated with Schizophrenia Epidemiology https://www.delveinsight.com/report-store/cognitive-impairment-associated-with-schizophrenia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Cognitive Impairment Associated with Schizophrenia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Aneurysmal Subarachnoid Hemorrhage Market https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market
DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cognitive Impairment Associated with Schizophrenia Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Cyclerion Therapeutics, Biogen, Neurocrine Bioscien here
News-ID: 3498139 • Views: …
More Releases from DelveInsight Business Research
Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therap …
According to DelveInsight's latest analysis, the global Spasticity pipeline features more than 10 active pharmaceutical companies that are advancing over 12 investigational therapies. The report offers a detailed evaluation of clinical trials, mechanisms of action, therapeutic approaches, routes of administration, and major developmental activities shaping the Spasticity treatment landscape.
DelveInsight's report, "Spasticity Pipeline Insight, 2025," delivers an extensive overview of the current clinical development environment and the future outlook for the…
Real-World Evidence Solution Market is set to grow at a 8.07% CAGR, reaching USD …
According to DelveInsight, the real-world evidence (RWE) solutions market is expanding rapidly, primarily due to the increasing global burden of chronic diseases and the growing need to improve healthcare outcomes. In addition, advancements in big data analytics, artificial intelligence, and machine learning are enhancing the ability to efficiently process and interpret large-scale real-world datasets. The rising adoption of RWE solutions by pharmaceutical and biotechnology companies - to support drug development,…
Spinal Implants Market is set to grow at a 5.50% CAGR, reaching USD 21.9 billion …
According to DelveInsight's assessment, the rising burden of spinal disorders particularly within the growing elderly population - continues to significantly increase the demand for surgical correction procedures. Alongside this, the surge in sports-related injuries and trauma cases is accelerating the need for advanced implantable spinal solutions. There is also a notable shift toward non-fusion and motion-preserving devices that support spinal flexibility and enhance patient outcomes, especially for younger and more…
Vascular Stents Market is set to grow at a 6.65% CAGR, reaching USD 18.28 billio …
According to DelveInsight's assessment, the rising global burden of cancer is significantly increasing the demand for advanced treatment approaches such as tumor ablation. Minimally invasive ablation techniques are gaining strong traction due to their advantages, including faster recovery times, lower complication risks, and reduced costs compared with traditional surgical procedures. At the same time, continuous improvements in ablation technologies - particularly in radiofrequency, microwave, and cryoablation systems - have enhanced…
More Releases for Cognitive
Internet User Surge Fuels Cognitive Media Market Growth Despite Cognitive Concer …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Cognitive Media Industry Market Size Be by 2025?
The size of the cognitive media market has experienced significant expansion lately. It is forecasted to increase from $2.14 billion in 2024 to $2.67 billion in 2025, reflecting a compound annual growth rate (CAGR) of 24.8%. The historic…
Cognitive Suites
Introducing cutting-edge technology-driven solutions and smart software applications tailor-made for diverse aviation stakeholders. Our comprehensive suite covers Airlines, General Aviation, Aviation Support Service Providers, Aviation Professionals, and Authorities of Airports and Air Navigation Service Providers (ANSP). Whether you're seeking enhanced operational efficiency, streamlined processes, or advanced data analytics, our solutions are designed to revolutionize the way you navigate the skies. Embrace the power of innovation and elevate your aviation experience…
The Future of Cognitive Intelligence: Analyzing the Booming Cognitive Computing …
Cognitive Computing Market Valued at 𝐔𝐒$ 𝟒𝟔.𝟓𝟒 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 in 2024, Projected to Reach US$ 285.72 Billion by 2033 at a CAGR of 22.30%
The cognitive computing market is witnessing unprecedented growth as industries integrate artificial intelligence (AI), machine learning (ML), natural language processing (NLP), and deep learning into their operations. These next-generation computing systems simulate human thought processes, allowing enterprises to analyze vast datasets, enhance decision-making, and optimize automation at an…
Cognitive Search Tools Market: Know Opportunity Ahead | Sinequa, Lucidworks, Cog …
HTF MI recently introduced Global Cognitive Search Tools Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status (2024-2032). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence. Some key players from the complete study Microsoft Corporation, IBM, Google, Amazon Web Services (AWS), Dassault Systèmes, Verint Systems, Elastic,…
Cognitive Services Market
With the watchful use of established and advanced tools such as SWOT analysis and Porter's Five Forces Analysis, this market report has been structured. While preparing this Cognitive Services Market research report, few of the attributes that have been adopted include highest level of spirit, practical solutions, committed research and analysis, innovation, integrated approaches, and most up-to-date technology. Every possible effort has been taken while researching and analysing information to…
Cognitive Computing Market worth Observing Growth: Saffron Technology, Cognitive …
Cognitive computing is an evolving model of intelligent computing system and methods that implements computational intelligence by autonomous perceptions and inferences imitating the mechanisms of the brain. The cognitive computing market has high growth prospects owing to increasingly complex and large datasets and the emergence of numerous computing platforms such as big data analytics, cloud, and mobile. Moreover, increasing demand from the end-use industries expected to fuel market growth during…
